Previous Close | 16.09 |
Open | 15.99 |
Bid | 16.11 x 3200 |
Ask | 16.12 x 3200 |
Day's Range | 16.00 - 16.12 |
52 Week Range | 12.28 - 17.15 |
Volume | |
Avg. Volume | 2,295,009 |
Market Cap | 51.216B |
Beta (5Y Monthly) | 0.68 |
PE Ratio (TTM) | 22.38 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 0.66 (4.10%) |
Ex-Dividend Date | Sept 29, 2022 |
1y Target Est | N/A |
Puma Biotechnology (PBYI), a top-ranked stock, has a promising development candidate, alisertib. Its only marketed product, Nerlynx (neratinib), is witnessing improving demand trends in the United States.
Lawyers for Peru's former President Alejandro Toledo filed for an emergency stay in a U.S. federal court on Thursday to block his extradition to the South American country, where he faces corruption charges. The lawyers argued in their early morning filing that a stay of his detention and extradition was "necessary to avoid imminent and irreparable harm of an erroneous deprivation of liberty, and possibly also life" if he is extradited by the Friday deadline set by a judge in California. The Pan American Health Organization (PAHO) is in preliminary talks with Japanese drugmaker Takeda over potential orders of its dengue vaccine, PAHO's director said on Thursday, though it has yet to decide whether it will recommend the shot.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
High-yield dividend stocks can be a great way to protect your portfolio from market volatility. Read on to find out more about these two high-yield dividend stocks. Ford, and most of its contemporaries, took a big step backward last year over concerns about the impact of rising interest rates on demand for new vehicles.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Unfortunately, Novavax (NASDAQ: NVAX) hasn't had great timing. The company was late to the party in winning authorizations for its COVID-19 vaccine, Nuvaxovid. If you only looked at Novavax's press releases, you wouldn't know about some recent bad news for the company.
Japan's Takeda Pharmaceutical Co posted a 13% drop in operating earnings for the nine months ended December but kept its profit outlook for the fiscal year unchanged as it works to bolster its drugs pipeline. Takeda's annual operating profit forecast of 530 billion yen already lags a Refinitiv analysts' consensus forecast of 593.9 billion yen. European Union regulators in December approved Takeda's vaccine for dengue fever, branded as QDENGA.
Japan's export growth slowed sharply in December as China-bound shipments fell for the first time in seven months, stoking fears of further slowdown in the global economy and external demand for Japanese shipments. Exports rose 11.5% year-on-year in December after a gain of 20% in November, marking the slowest growth since the start of 2022, dragged down by a fall-off in sales to China of cars, auto parts and chip-making machinery, Ministry of Finance (MOF) data showed on Thursday. Exports to largest trading partner China fell 6.2% year-on-year in value and were down 24% in volume terms in December.
Takeda Pharmaceutical will buy U.S.-based Nimbus Therapeutics' experimental psoriasis drug for up to $6 billion, the Japanese drugmaker said on Tuesday, as it looks to cut reliance on treatments facing loss of patents. The drug, codenamed "NDI-034858", last week showed statistically significant reduction in moderate-to-severe psoriasis in a mid-stage study and is expected to enter late-stage trials next year. The company is also studying the drug to treat inflammatory bowel disease and psoriatic arthritis.
A dengue vaccine developed by Japanese drugmaker Takeda Pharmaceutical Co was authorised for use in the European Union on Thursday, making it the second approved inoculation against the mosquito-borne disease that causes millions of infections annually. The vaccine, branded QDENGA, is authorized for use in those aged 4 and older to prevent any of the four so-called serotypes of dengue. Between 20,000 and 25,000 people, mostly children, die each year from the virus, according to the World Health Organization.
The biopharmaceutical company specializes in cancer therapies. Its stock got a boost on Monday when a Takeda Pharmaceutical (NYSE: TAK) candidate, ponatinib, hit its primary goal in a phase 3 clinical trial as a treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia. The blood cancer therapy works by slowing the activity of BCR-ABL1, a gene sequence found in an abnormal chromosome 22, often seen in people with certain types of leukemia.
Are these a couple of rare opportunities that investors shouldn't pass up, or are the price drops valid because of significant concerns that should keep you away from these companies? Takeda is a Japan-based healthcare company that makes vaccines and pharmaceutical products.
One happy consequence of a bear market is that dividend yields rise as stock prices fall. Three beaten-up stocks trading near their 52-week lows that could be especially attractive right now include Takeda Pharmaceuticals (NYSE: TAK), Duke Energy (NYSE: DUK), and Home Depot (NYSE: HD). Japanese drugmaker Takeda Pharmaceuticals is a leading healthcare company that makes vaccines and products addressing multiple therapeutic areas, including cancer, rare diseases, gastroenterology, and hematology.
TAK vs. ZTS: Which Stock Is the Better Value Option?
Puma Biotechnology (PBYI) inks license agreement with Japan's Takeda Pharmaceuticals, gaining worldwide development and commercialization rights to the latter's cancer treatment alisertib.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
When dividend stocks dip in price and go on sale, they can create buying opportunities for long-term investors. Takeda Pharmaceuticals (NYSE: TAK) and Verizon Communications (NYSE: VZ) are both at multi-year lows, and here's why they could be attractive options for a $5,000 investment. Takeda Pharmaceuticals is one of the largest drug companies in the world.
TAK vs. ZTS: Which Stock Is the Better Value Option?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
TAK vs. ZTS: Which Stock Is the Better Value Option?
Q1 2023 Olympus Corp Earnings Presentation
The consensus price target hints at a 26.4% upside potential for Takeda Pharmaceutical Co. (TAK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
TOKYO (Reuters) -Japan's biggest drugmaker Takeda Pharmaceutical Co reported a sharp drop in first-quarter profit on Thursday, reflecting one-off gains a year earlier, while maintaining annual earnings forecasts that are buoyed by the yen's decline. In the first quarter of last fiscal year, Takeda benefited from a one-time gain of 131.4 billion yen when it sold off its diabetes assets to refocus on core businesses following its acquisition of Shire Plc. The next major driver for Takeda's earnings and shares may be a decision by European regulators, expected later this year, on the company's experimental vaccine for Dengue fever.
Japan's biggest drugmaker Takeda Pharmaceutical Co reported a sharp drop in first-quarter profit on Thursday, reflecting one-off gains a year earlier, while maintaining annual earnings forecasts that are buoyed by the yen's decline. In the first quarter of last fiscal year, Takeda benefited from a one-time gain of 131.4 billion yen when it sold off its diabetes assets to refocus on core businesses following its acquisition of Shire Plc. The next major driver for Takeda's earnings and shares may be a decision by European regulators, expected later this year, on the company's experimental vaccine for Dengue fever.